Рет қаралды 15
Moritz Fürstenau, MD, discusses the rationale for launching the phase 3 GAIA/CLL13 in previously untreated, fit patients with chronic lymphocytic leukemia.
Website: www.onclive.com
Twitter: / onclive
Facebook: / onclive
LinkedIn: / onclive